Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

728
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
728
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
917
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

485
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
485
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

324
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
324

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interobserver variability in synovial tissue biopsy markers in Rheumatoid Arthritis: Results from OMERACT special interest group on synovial tissue biopsy.

Seminars in arthritis and rheumatism·2026
Same author

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study.

European journal of breast health·2026
Same author

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Frontiers in immunology·2026
Same author

Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs.

Orphanet journal of rare diseases·2026
Same author

Long-term comorbidity patterns in juvenile idiopathic arthritis.

Clinical and experimental rheumatology·2026
Same author

Comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset.

Clinical and experimental rheumatology·2026

Related Experiment Video

Updated: Mar 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

Biosimilar DMARDs: What Does the Future Hold?

Filipe Araújo1,2, João Gonçalves3, João Eurico Fonseca4,5

  • 1Rheumatology Unit, Hospital Ortopédico de Sant'Ana, SCML, Lisbon, Portugal.

Drugs
|March 5, 2016
PubMed
Summary

Biological medicinal products offer hope for inflammatory rheumatic diseases but are costly. CT-P13, the first infliximab biosimilar, marks a milestone in improving access and affordability for these vital treatments.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.0K

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Biological disease-modifying anti-rheumatic drugs (DMARDs) are crucial for inflammatory rheumatic diseases but pose economic challenges.
  • The development of biosimilars aims to reduce costs and increase accessibility while maintaining quality, efficacy, and safety comparable to reference biologics.
  • The European Medicines Agency's approval of CT-P13, a biosimilar of infliximab, represents a significant advancement in this field.

Purpose of the Study:

  • To provide a comprehensive overview of biosimilar DMARDs, including their manufacturing and regulatory processes.
  • To review the non-clinical and clinical data supporting the approval of CT-P13 and discuss emerging biosimilars.
  • To address key issues such as indication extrapolation, interchangeability, and automatic substitution for biosimilars.

Main Methods:

  • Review of regulatory guidelines for biosimilar comparability assessments.
  • Analysis of non-clinical and clinical trial data for CT-P13.
  • Examination of current clinical evidence for other developing biosimilars.
  • Discussion of regulatory and clinical considerations for biosimilar adoption.

Main Results:

  • CT-P13, the first monoclonal antibody biosimilar (infliximab), has been approved, demonstrating similar quality, efficacy, and safety to the reference product.
  • Growing evidence supports the use of biosimilars, gradually reducing controversies and increasing physician and patient confidence.
  • Further data and clarification on uncertainties surrounding biosimilar agents are needed to ensure widespread adoption and trust.

Conclusions:

  • Biosimilar DMARDs, exemplified by CT-P13, offer a promising avenue to enhance patient access to essential treatments for rheumatic diseases.
  • The rigorous comparability exercise ensures that biosimilars meet high standards, comparable to their reference products.
  • Continued evidence generation and clear regulatory pathways are essential for the successful integration of biosimilars into clinical practice and healthcare systems.